Lee et al., 2022 - Google Patents
Anti-obesity effects of agar (Gelidium amansii)-derived oligosaccharides in high-fat diet-treated C57BL/6N mice due to differential regulations of lipogenesis and …Lee et al., 2022
- Document ID
- 991505448814723181
- Author
- Lee M
- Kim J
- Jin Y
- Roh Y
- Seol A
- Song H
- Jung M
- Hong J
- Jang M
- Hwang D
- Publication year
- Publication venue
- Bioscience, Biotechnology, and Biochemistry
External Links
Snippet
To investigate the effects of agar oligosaccharides (AO) on lipid metabolism, changes in obesity phenotypes and related molecular factors were evaluated in C57BL/6N mice fed a high-fat diet (HFD). When HFD-induced obese mice were fed AO, they lost weight. Also, fat …
- 235000009200 high fat diet 0 title abstract description 71
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Polysaccharide from Rosa roxburghii Tratt fruit attenuates hyperglycemia and hyperlipidemia and regulates colon microbiota in diabetic db/db mice | |
| Chen et al. | Tea polysaccharides as potential therapeutic options for metabolic diseases | |
| Lv et al. | Polysaccharide peptides from Ganoderma lucidum ameliorate lipid metabolic disorders and gut microbiota dysbiosis in high-fat diet-fed rats | |
| Si et al. | Gut microbiome‐induced shift of acetate to butyrate positively manages dysbiosis in high fat diet | |
| Wan et al. | Physicochemical characterization of a polysaccharide from green microalga Chlorella pyrenoidosa and its hypolipidemic activity via gut microbiota regulation in rats | |
| Sumiyoshi et al. | Low molecular weight chitosan inhibits obesity induced by feeding a high‐fat diet long‐term in mice | |
| Song et al. | Effects of three different mannans on obesity and gut microbiota in high-fat diet-fed C57BL/6J mice | |
| Zhao et al. | Inhibition of azoxymethane-induced preneoplastic lesions in the rat colon by a cooked stearic acid complexed high-amylose cornstarch | |
| Deng et al. | Highland barley whole grain (Hordeum vulgare L.) ameliorates hyperlipidemia by modulating cecal microbiota, miRNAs, and AMPK pathways in leptin receptor-deficient db/db mice | |
| Jiang et al. | Cholesterol-lowering effects and potential mechanisms of chitooligosaccharide capsules in hyperlipidemic rats | |
| Shimoi et al. | Absorption and urinary excretion of quercetin, rutin, and αG-rutin, a water soluble flavonoid, in rats | |
| Zhang et al. | Study on Dendrobium officinale O-Acetyl-glucomannan (Dendronan). 7. Improving effects on colonic health of mice | |
| Yu et al. | The progress of nomenclature, structure, metabolism, and bioactivities of oat novel phytochemical: avenanthramides | |
| Nielsen et al. | Effects of resistant starch and arabinoxylan on parameters related to large intestinal and metabolic health in pigs fed fat-rich diets | |
| Kawabata et al. | Citrus kawachiensis peel powder reduces intestinal barrier defects and inflammation in colitic mice | |
| Li et al. | Deacetylated konjac glucomannan is less effective in reducing dietary-induced hyperlipidemia and hepatic steatosis in C57BL/6 mice | |
| Honoré et al. | Smallanthus sonchifolius (yacon) flour improves visceral adiposity and metabolic parameters in high‐fat‐diet‐fed rats | |
| Li et al. | Stropharia rugoso-annulata acetylated polysaccharides alleviate NAFLD via Nrf2/JNK1/AMPK signaling pathways | |
| Jang et al. | Agrimonia pilosa Ledeb. aqueous extract improves impaired glucose tolerance in high-fat diet-fed rats by decreasing the inflammatory response | |
| Li et al. | 4-O-Sulfation in sea cucumber fucodians contribute to reversing dyslipidiaemia caused by HFD | |
| Perez Gutierrez et al. | Ameliorative Effect of Hexane Extract of Phalaris canariensis on High Fat Diet‐Induced Obese and Streptozotocin‐Induced Diabetic Mice | |
| Zhang et al. | Smilax China L. polysaccharide prevents HFD induced-NAFLD by regulating hepatic fat metabolism and gut microbiota | |
| Shang et al. | Studies on the unique properties of resistant starch and chito-oligosaccharide complexes for reducing high-fat diet-induced obesity and dyslipidemia in rats | |
| Cheng et al. | Hepatoprotective effects of chlorogenic acid on mice exposed to aflatoxin B1: Modulation of oxidative stress and inflammation | |
| Wu et al. | Inhibition of advanced glycation endproducts formation by lotus seedpod oligomeric procyanidins through RAGE-MAPK signaling and NF-κB activation in high-AGEs-diet mice |